Thus, all these data indicated that pretreatment with Mito-TEMPO or Mdivi-1 notably relieved the inflammation induced by MSU crystals in vivo, and that targeting mitochondrial ROS or Drp1 activity may be potential candidates for the treatment of gouty arthritis in the future. Here, DNM1L is linked to gout.